Madrigal reports Q4 Rezdiffra sales $321M, FY $958M; pipeline expands with siRNA and GLP-1 deals

MADRIGAL PHARMACEUTICALS, INC.

2025-FY EPS reported -$12.85 revenue$958,403,000

Q4 2025 Rezdiffra net sales $321.1M; full-year net sales $958.4M, vs $180.1M in 2024.
More than 36,250 patients on Rezdiffra as of year-end 2025.
Cash, equivalents and marketable securities $988.6M as of Dec. 31, 2025.
Licensed global rights to six pre-clinical siRNA programs and oral GLP-1 (MGL-2086) to combine with Rezdiffra.
Secured Orange Book listed Rezdiffra patent with protection into 2045; also closed $500M credit facility.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.